8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2021 / Multicenter randomized controlled trial
The OMEMI trial evaluated whether adding 1.8 g of n-3 PUFA (930 mg EPA and 660 mg DHA) daily versus corn oil placebo to standard of care reduced cardiovascular events over 2 years in patients aged 70 to 82 years with recent AMI. Among 1014 analyzed patients, the primary composite endpoint occurred in 21.4% (108/505) of the n-3 PUFA group and 20.0% (102/509) of the placebo group (HR 1.08 [95% CI, 0.82-1.41]; P=0.60). New atrial fibrillation occurred in 7.2% vs 4.0% (HR 1.84 [95% CI, 0.98-3.45]; P=0.06), and major bleeding occurred in 10.7% vs 11.0% (P=0.87). The authors concluded they could not detect a reduction in clinical events with 1.8 g n-3 PUFAs daily for 2 years in this population.
Kalstad AA, Myhre PL, Laake K, et al. Circulation, 2021. PMID 33191772
2021 / Randomized controlled trial
A randomized controlled trial assigned 48 obese women with PCOS to receive a low-calorie diet with either 5 g/day thylakoid-rich spinach extract or 5 g/day placebo for 12 weeks. Compared to placebo, the spinach extract group had a greater increase in serum omentin-1 (10.90 vs. 3.87 ng/L; p < .001) and greater reductions in fat mass (-5.19 vs. -1.35 kg; p < .001), neopterin (-0.66 vs. -0.38 nmol/L; p = .003), and chemerin (-41.24 vs. -11.26 ng/L; p < .001). Significant decreases in other anthropometric indices and insulin resistance were also observed in the thylakoid group compared to placebo (p < .001 for all parameters).
Pourteymour Fard Tabrizi F, Abbasalizad Farhangi M, Vaezi M, et al. Phytother Res, 2021. PMID 33368745
2021 / Prospective single-arm pilot study
Ten cirrhotic patients experiencing muscle cramps at least once per week were administered an oral taurine solution (1 g thrice daily) for 4 weeks, followed by a 4-week discontinuation. Muscle cramp scores decreased in seven patients by weeks 4 and 8. Median cramp scores dropped from 21 (IQR: 8-84) at baseline to 6.5 (IQR: 3-12, p=0.126) at week 4 and 5 (IQR: 1.5-56, p=0.066) at week 8. Improvements in muscle cramps at week 4 were reported by 60% of patients with low baseline taurine levels and 80% of patients with normal or higher baseline levels.
Jang ES, Hwang SH, Kim JW, et al. Yonsei Med J, 2021. PMID 33381931
2021 / Double-blinded, placebo-controlled, randomized crossover trial
In a double-blind, placebo-controlled crossover study, 15 participants with type 2 diabetes underwent two 14-day treatment periods with acarbose or placebo. At the end of each period, participants underwent liquid mixed meal tests with concomitant infusion of the GLP-1 receptor antagonist exendin(9-39)NH2 or saline. Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. While no absolute difference was observed in exendin(9-39)NH2-induced glucose excursions between periods, postprandial glucose relatively increased by 119 ± 116% during exendin(9-39)NH2 infusion in the acarbose period versus 39 ± 27% in the placebo period (P = 0.0163).
Dalsgaard NB, Gasbjerg LS, Hansen LS, et al. Eur J Endocrinol, 2021. PMID 33449919
2021 / Prospective randomised double-blind sham-controlled study
In a prospective randomised double-blind sham-controlled trial, 62 participants with mild cognitive impairment were allocated to whole-body cryotherapy (-110 °C to -160 °C; n = 33) or a placebo control group (n = 29). After the 10th session (T2), significant differences favored the cryotherapy group in immediate recall (DemTect) and orientation (TYM). Improvements in mood were detected in self-reported depressive symptoms (T2 p = 0.04; VAS mood T2 p = 0.02; T3 p = 0.07), alongside a significant reduction in BDNF level (p < 0.05).
Rymaszewska J, Lion KM, Stańczykiewicz B, et al. Exp Gerontol, 2021. PMID 33454354
2021 / Randomized crossover inpatient trial
Twenty inpatients were randomized to consume ad libitum either a minimally processed, plant-based, low-fat diet (10.3% fat, 75.2% carbohydrate) or an animal-based, ketogenic, low-carbohydrate diet (75.8% fat, 10.0% carbohydrate) for 2 weeks, followed immediately by the alternate diet. One participant withdrew due to hypoglycemia during the low-carbohydrate diet. The low-fat diet led to 689 ± 73 kcal d-1 less energy intake over 2 weeks (P < 0.0001) and 544 ± 68 kcal d-1 less over the final week (P < 0.0001) compared to the low-carbohydrate diet.
Hall KD, Guo J, Courville AB, et al. Nat Med, 2021. PMID 33479499
2021 / Randomized controlled trial
A randomized trial investigated whether daily oral almond consumption increases UVB resistance and reduces skin aging in 39 healthy Asian women (18-45 years, Fitzpatrick skin type II-IV). Participants consumed either 1.5 oz of almonds or 1.8 oz of pretzels daily for 12 weeks. The minimal erythema dose (MED) increased in the almond group compared to the pretzel group. No differences were observed between groups in facial Allergan roughness, melanin, hydration, or sebum.
Li JN, Henning SM, Thames G, et al. J Cosmet Dermatol, 2021. PMID 33491323
2021 / Supplementation trial
Eight male participants received 1000 mg/day of nicotinamide riboside (NR) or cellulose placebo for 1 week to evaluate metabolic and skeletal muscle responses to a 1-hour cycling bout. NR supplementation had no effect on substrate utilization at rest or during exercise, nor on skeletal muscle mitochondrial respiration. It also did not alter skeletal muscle NAD+ concentration, global acetylation, auto-PARylation of PARP1, or acetylation of p53 Lys382 and MnSOD Lys122. However, NR increased concentrations of deaminated NAD+ precursors (NAR and NAM) and methylated breakdown products (Me2PY and Me4PY).
Stocks B, Ashcroft SP, Joanisse S, et al. J Physiol, 2021. PMID 33492681
2021 / Randomized, double-blind, placebo-controlled crossover trial & in vitro study
Researchers investigated the effects of nicotinamide riboside (NR) on brown adipose tissue (BAT) in mice, in vitro human adipocytes, and human volunteers. In vitro, NR enhanced norepinephrine-stimulated mitochondrial uncoupling in primary adipocytes from human BAT. However, in a randomized, double-blind, placebo-controlled crossover study of human volunteers receiving 1000 mg/day NR for 6 weeks, NR supplementation did not alter in vivo BAT activity or cold-induced thermogenesis.
Nascimento EBM, Moonen MPB, Remie CME, et al. J Clin Endocrinol Metab, 2021. PMID 33524145
2021 / Randomized comparative trial
Sixty patients with female pattern hair loss were randomized to receive either pumpkin seed oil (n = 30) or minoxidil 5% foam (n = 30) for 3 months. In the pumpkin seed oil group, hair shaft diversity significantly decreased from 30.5 ± 6.2% to 24.0 ± 4.02 (P < .001) and vellus hairs decreased from 22.5 ± 4.9 to 15.8 ± 2.2 (P < .001), while upright regrowing hairs increased from 0.13 ± 0.5 to 0.9 ± 1.0 (P < .001). In the minoxidil group, hair shaft diversity decreased from 31.5 ± 6.3% to 21.3 ± 2.2 (P < .001) and vellus hairs decreased from 24.7 ± 6.4 to 19.5 ± 5.4 (P = .02).
Ibrahim IM, Hasan MS, Elsabaa KI, et al. J Cosmet Dermatol, 2021. PMID 33544448
2021 / Randomized between-subjects trial
Preschoolers were randomized to either a FRUIT ONLY smoothie condition (n=36) or a FRUIT+DGV smoothie condition containing spinach, collards, and kale (n=32) to measure acceptance and ad libitum intake. In the FRUIT+DGV condition, 84.3% of children willingly tasted all five green smoothies, rating them as moderately liked (2.3 ± 0.1). During an ad libitum snack session, children in the FRUIT+DGV condition drank 225.7 ± 31.4 g of their most preferred green smoothie, delivering 18.3 ± 3.7 g of dark green vegetables and meeting 31% of their weekly USDA recommendations. Willingness to try, liking, and total intake did not differ significantly between smoothie conditions.
Rollins BY, Stein W, Keller KL, et al. Appetite, 2021. PMID 33549836
2021 / Randomized controlled trial
In a 1-year randomized controlled trial, 208 healthy older adults were assigned to carbohydrate (CARB), collagen (COLL), whey protein (WHEY), light resistance training plus whey (LITW), or heavy resistance training plus whey (HRTW). COLL and WHEY alone did not affect any measured parameter compared to CARB. Compared to WHEY, HRTW increased quadriceps cross-sectional area (+1.68 cm2; 95% CI: +0.41 to +2.95 cm2; P = 0.03), dynamic strength (+18.4 Nm; P < 10-4), and isometric strength (+23.9 Nm; P < 10-5), while LITW improved dynamic knee extensor strength (+13.7 Nm; P = 0.01) without improving muscle size.
Mertz KH, Reitelseder S, Bechshoeft R, et al. Am J Clin Nutr, 2021. PMID 33564844
2021 / Double-blind randomized controlled trial
In a double-blind trial, 1961 adults with overweight or obesity without diabetes were randomly assigned (2:1) to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with lifestyle intervention. Mean body weight change was -14.9% with semaglutide compared to -2.4% with placebo (difference -12.4 percentage points; P<0.001), representing a -15.3 kg vs. -2.6 kg change. Significantly more semaglutide participants achieved weight reductions of ≥5% (86.4% vs. 31.5%), ≥10% (69.1% vs. 12.0%), and ≥15% (50.5% vs. 4.9%). Transient, mild-to-moderate nausea and diarrhea were the most common adverse events, with 4.5% of semaglutide participants discontinuing treatment due to gastrointestinal events versus 0.8% with placebo.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med, 2021. PMID 33567185
2021 / Randomized controlled trial
In a randomized trial, 78 women aged 18-40 years with PCOS received either 1000 mg resveratrol or 1000 mg placebo daily for 3 months. Compared to placebo, the resveratrol group had a significantly higher regular menstruation rate (76.47% vs. 51.61%; p = 0.03) and lower hair loss (32.10% vs. 68.00%; p = 0.009). No significant differences were found between groups for ovarian and adrenal androgens, SHBG, FAI, glycoinsulinemic metabolism, or lipid profile, and weight did not change relative to placebo.
Mansour A, Samadi M, Sanginabadi M, et al. Clin Nutr, 2021. PMID 33610422
2021 / Randomized, double-blind, parallel-group trial
A 68-week trial randomized 611 adults with overweight or obesity to once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with intensive behavioral therapy and an initial 8-week low-calorie diet. At week 68, estimated mean body weight change was -16.0% with semaglutide compared to -5.7% with placebo (difference: -10.3 percentage points, P < .001). Significantly more participants in the semaglutide group achieved weight losses of at least 5% (86.6% vs 47.6%), 10% (75.3% vs 27.0%), and 15% (55.8% vs 13.2%). Gastrointestinal adverse events occurred in 82.8% of semaglutide participants versus 63.2% with placebo, causing discontinuation in 3.4% and 0%, respectively.
Wadden TA, Bailey TS, Billings LK, et al. JAMA, 2021. PMID 33625476
2021 / Randomized, double-blind, double-dummy, placebo-controlled trial
In this 68-week trial, 1210 adults with type 2 diabetes and a BMI of at least 27 kg/m2 were randomized to receive weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo, alongside a lifestyle intervention. Estimated mean bodyweight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo (difference -6.2 percentage points, 95% CI -7.3 to -5.2; p<0.0001). Significantly more patients taking semaglutide 2.4 mg achieved at least 5% weight reduction compared to placebo (68.8% vs 28.5%; OR 4.88, 95% CI 3.58 to 6.64; p<0.0001). Adverse events, particularly gastrointestinal events, were more common with semaglutide 2.4 mg (87.6% total, 63.5% gastrointestinal) than with placebo (76.9% total, 34.3% gastrointestinal).
Davies M, Færch L, Jeppesen OK, et al. Lancet, 2021. PMID 33667417
2021 / Randomized, double-blind, phase 3a withdrawal trial
Following a 20-week run-in with subcutaneous semaglutide resulting in a mean weight loss of 10.6%, 803 participants were randomized to 48 weeks of continued semaglutide (2.4 mg/week) or placebo, both with lifestyle intervention. From week 20 to 68, participants continuing semaglutide had a mean weight change of -7.9% compared to +6.9% with placebo (difference: -14.8 percentage points, P < .001). Continued semaglutide also led to greater improvements in waist circumference (-9.7 cm), systolic blood pressure (-3.9 mm Hg), and physical functioning scores. Gastrointestinal adverse events were reported in 49.1% of semaglutide participants versus 26.1% with placebo, though discontinuation rates due to adverse events were similar (2.4% vs 2.2%).
Rubino D, Abrahamsson N, Davies M, et al. JAMA, 2021. PMID 33755728
2021 / 10-week randomized, placebo-controlled, double-blind trial
A 10-week, randomized, placebo-controlled, double-blind trial evaluated the effects of nicotinamide mononucleotide (NMN) supplementation on metabolic function in overweight or obese postmenopausal women with prediabetes. Insulin-stimulated glucose disposal, evaluated using a hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling (AKT and mTOR phosphorylation) increased after NMN supplementation but did not change after placebo. Additionally, NMN supplementation up-regulated platelet-derived growth factor receptor β and other genes involved in muscle remodeling.
Yoshino M, Yoshino J, Kayser BD, et al. Science, 2021. PMID 33888596
2021 / Double-blind, randomized, placebo-controlled trial
A double-blind, placebo-controlled trial evaluated daily supplementation with a fruit and vegetable concentrate (FVC) and high-fiber component across 57 pre-menopausal, overweight/obese female healthcare workers over five months. FVC supplementation had no effect on blood lipids, glucose, or immune parameters, but improved glucose clearance. FVC did not alter phyla-level taxonomy or alpha/beta diversity, but reduced Bacteroides abundance and increased fecal butyrate; adding a high-fiber component improved levels of health-associated bacteria.
van der Merwe M, Moore D, Hill JL, et al. Microorganisms, 2021. PMID 33920059
2021 / Videorecorded laboratory feeding experiment
In the Good Tastes Study, 106 caregiver-child dyads (children aged 6-24 months) were offered 4 versions of puréed kale: plain, 1.2% or 1.8% added sugar, or 0.2% added salt. Infants 6 to <12 months accepted more tastes (b = 2.911, P < 0.001) and were rated by caregivers as liking kale more than toddlers ≥18 months (b = 1.874, P = 0.014). Plain kale was more likely to be accepted (P < 0.001), showing no advantage of bitterness reduction by adding sugar or salt. The authors concluded there may be a sensitive period during early complementary feeding to improve success introducing novel bitter foods.
Johnson SL, Moding KJ, Grimm KJ, et al. J Nutr, 2021. PMID 34191021
2021 / Randomized, double-blind, controlled trial
A randomized, double-blind, controlled trial evaluated the effects of 32 days of NAD+-precursor supplementation (207.5 mg niacin equivalents/day from tryptophan, nicotinic acid, and nicotinamide) versus control in 14 older adults with impaired physical function. Skeletal muscle NAD+ concentrations were not significantly different between intervention and control (7.5 ± 1.9 vs 7.9 ± 1.6 AU), although methyl-nicotinamide levels were significantly higher (0.098 ± 0.063 vs 0.025 ± 0.014; P = 0.001). Neither ADP-stimulated mitochondrial respiration (82.1 ± 19.0 vs 84.0 ± 19.2; P = 0.716), maximally uncoupled mitochondrial respiration (103.4 ± 30.7 vs 108.7 ± 33.4; P = 0.495), nor net exercise efficiency (20.2 ± 2.77 vs 20.8 ± 2.88; P = 0.342) improved with supplementation.
Connell NJ, Grevendonk L, Fealy CE, et al. J Nutr, 2021. PMID 34191033
2021 / Interventional trial and metagenomic reanalysis
Researchers analyzed gut metagenomes from healthy antibiotic-naïve humans supplemented with an 11-probiotic-strain preparation, alongside mouse models and a separate human cohort receiving antibiotics. Probiotics reduced the number of antibiotic resistance genes exclusively in the gut of colonization-permissive, antibiotic-naïve individuals. Following antibiotics, probiotics exacerbated resistome expansion in GI mucosa by supporting a bloom of strains with vancomycin resistance genes, unlike autologous fecal microbiome transplantation or spontaneous recovery. These mucosal effects were not reflected in stool samples.
Montassier E, Valdés-Mas R, Batard E, et al. Nat Microbiol, 2021. PMID 34226711
2021 / Randomized, double-blind, placebo-controlled, 4-arm clinical trial
A 6-week randomized, double-blind, placebo-controlled trial evaluated 48 recreationally trained runners assigned to placebo or 300, 600, or 1200 mg/day of nicotinamide mononucleotide (NMN) alongside 40-60 minute exercise sessions 5-6 times weekly. Oxygen uptake (VO2), percentages of VO2max, and power at both the first and second ventilatory thresholds increased to a higher degree in the medium and high dosage groups compared to control. However, there was no difference in VO2max, O2-pulse, VO2 related to work rate, or peak power after the 6-week treatment from baseline across any groups.
Liao B, Zhao Y, Wang D, et al. J Int Soc Sports Nutr, 2021. PMID 34238308
2021 / Randomized controlled trial
Postmenopausal women were randomly assigned to a low-fat, vegan diet including 1/2 cup (86 g) of cooked soybeans daily, or to no diet changes for 12 weeks. Total hot flashes decreased 79% in the intervention group compared to 49% in controls (between-group P = 0.01), and moderate-to-severe hot flashes decreased 84% versus 42% (between-group P = 0.01). Furthermore, 59% (10/17) of the intervention group became free of moderate and severe hot flashes, while the control group saw no change (between-group P < 0.001). Significantly greater improvements were also observed in the intervention group across vasomotor, psychosocial, physical, and sexual quality of life domains.
Barnard ND, Kahleova H, Holtz DN, et al. Menopause, 2021. PMID 34260478